IntelGenx Technologies Corp. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-08: Form 8-K; Period of report 2021-12-07; Description 8.01 Other Events.
- 2021-09-15: Form 8-K; Period of report 2021-09-14; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.01.
- 2021-08-11: Form 8-K; Period of report 2021-08-11; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2021-08-04: Form 8-K; Period of report 2021-08-04; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-08 | 8-K | 2021-12-07 | 8.01 Other Events | form8k.htm | |
| 2021-09-15 | 8-K | 2021-09-14 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 In connection with the proposed up-listing from the TSX Venture Exchange to the Toronto Stock Exchange of common shares, warrants and debentures of IntelGenx Technologies Corp. (the "Corporation") as set out in the conditional approval letter of the Toronto Stock Exchange dated August 12, 2021 (the "Up-Listing"), on September 14, 2021, ATAI Life Sciences AG ("atai") and IntelGenx Corp. (the "IntelGenx"), a wholly owned subsidiary of the Corporation, agreed to amend and restate the existing loan agreement dated March 8, 2021, as previously amended on May 14, 2021 (as amended and restated, the "Loan Agreement"), for the purpose of increasing the principal amount of loans available to IntelGenx and extending the maturity date of the loans to January 5, 2024. atai already advanced a tranche in the amount of $2,000,000 to IntelGenx on March 8, 2021 and a second tranche in the amount of $500,000 on May 14, 2021. atai has agreed to provide a third tranche in the amount of $3,000,000 to IntelGenx on or about January 7, 2022 and a fourth tranche on about January 6, 2023 in the amount of $3,000,000, subject in each case to certain conditions. 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K under the headings "Loan Agreement" and "Deed of Hypothec" is incorporated by reference into this Item 2.03. | form8k.htm |
| 2021-08-11 | 8-K | 2021-08-11 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On August 5, 2021 (the "Closing Date"), IntelGenx Technologies Corp. (the "Company") closed an offering by way of private placement in the United States (the "Private Placement") of unsecured convertible notes (the "Notes"). 2.03 The disclosure set forth in Item 1.01 to this Current Report on Form 8-K is incorporated into this item by reference. 3.02 The disclosure set forth in Item 1.01 to this Current Report on Form 8-K is incorporated into this item by reference. | form8k.htm |
| 2021-08-04 | 8-K | 2021-08-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 2, 2021, the board of directors (the "Board") of IntelGenx Technologies Corp. (the "Corporation") increased the size of the Board from six (6) to eight (8) and appointed Mr. Srinivas Rao and Mr. Frank Stegert to the Board. | form8k.htm |
| 2021-05-25 | 8-K | 2021-05-24 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.03 Material Modification to Rights of Security Holders | 1.01 On April 9, 2021, the Company announced its intention to amend the terms of its 6% Subordinated Convertible Unsecured Promissory Notes dated May 8, 2018 (the "Notes"), subject to approval of the TSX Venture Exchange and holders holding a majority of the aggregate outstanding principal amount of the Notes. 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.03 in its entirety. 3.03 The information set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 3.02 in its entirety. | form8k.htm |
| 2021-05-17 | 8-K | 2021-05-14 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On May 14, 2021 (the "Initial Closing Date"), IntelGenx Technologies Corp. (the "Corporation") issued (i) 37,300,000 shares of common stock of the Corporation (the "Shares"), (ii) 22,380,000 warrants (the "Warrants") and (iii) a unit purchase warrant (the "Additional Unit Warrant") to purchase up to 130,000,000 additional units ("Additional Units"), to ATAI Life Sciences AG ("atai") for aggregate gross proceeds of US$12,346,300 (the "Investment"), pursuant to an amended and restated securities purchase agreement (the "Securities Purchase Agreement") entered into by the Corporation and atai on the Initial Closing Date. 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K under the heading "Amendment to Term Loan" is incorporated by reference into this Item 2.03. 3.02 The information set forth under Item 1.01 of this Current Report on Form 8-K under the heading "Securities Purchase Agreement" is hereby incorporated by reference into this Item 3.02 in its entirety. | form8k.htm |
| 2021-05-12 | 8-K | 2021-05-11 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 IntelGenx Technologies Corp. (the "Company" or "IntelGenx") held its Annual Meeting of Shareholders on May 11, 2021 (the "Annual Meeting"), in a virtual-only format, for those who were shareholders of the Company at the close of business on March 19, 2021 (the "Record Date"), pursuant to notice and proxy materials duly communicated to them. | form8k.htm |
| 2021-03-15 | 8-K | 2021-03-09 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On March 14, 2021, IntelGenx Corp. (the "IntelGenx"), a wholly owned subsidiary of IntelGenx Technologies Corp. (the "Corporation"), entered into a strategic development agreement (the "Strategic Development Agreement") with ATAI Life Sciences AG ("atai"). 2.03 The information set forth under Item 1.01 of this Current Report on Form 8-K under the heading "Term Loan" is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 of this Current Report on Form 8-K under the heading "Securities Purchase Agreement" is hereby incorporated by reference into this Item 3.02 in its entirety. | form8k.htm |
| 2021-01-14 | 8-K | 2021-01-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 The Board of Directors of IntelGenx Technologies Corp. (the "Company") announced today, that it has appointed Tommy Kenny, to serve as Vice President, Intellectual Property and Legal Affairs, General Counsel of IntelGenx Corp., the Company's operating subsidiary, pursuant to the terms and conditions of a Memorandum of Agreement (the "Agreement"). 8.01 On January 12, 2021, the Company issued a press release announcing the appointment of Mr. Kenny. | form8k.htm |
| 2021-01-05 | 8-K | 2020-12-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 Saint Laurent, Quebec, January 5, 2021` - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (the "Company" or "IntelGenx") announced that on December 31, 2020, it issued 887,880 common shares at a deemed price of C$0.335 per Common Share in payment of an aggregate of C$297,440 in interest owing on the Corporation's 8.00% convertible unsecured subordinated debentures due June 30, 2022 (the "Debentures"). | form8k.htm |